Codiak BioSciences

Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines. $CDAK

[Codiak BioSciences @codiakbio]

We’re proud to recognize Senior Scientist, Michael Doherty, speaking virtually today at the Biologics Manufacturing Asia 2023 conference in Singapore. His presentation highlights Codiak’s pioneering work in manufacturing engineered exosomes. https://t.co/dVZlC8gn9p

[Codiak BioSciences @codiakbio]

Through case studies based on successful process development, Matt Brown will present on the evolution of exosome manufacturing technology from batch to continuous and highlight further opportunities for integrated, continuous bioprocessing. See you at the CCP Summit!

[Codiak BioSciences @codiakbio]

Today we recognize the amazing women at Codiak, and all of the amazing (and upcoming) women scientists working to understand and improve our world. #February11 #WomeninScience #STEM #ThinkScienceThinkPeace #biotech

[Codiak BioSciences @codiakbio]

Recognizing Andrew Wood, who presented at the CMC Strategy Forum last week. His talk highlighted the evolution of Codiak’s approach to delivering oligonucleotides with exosomes & optimization strategies for surface-bound ASOs, including payload attachment and linker design.

[Codiak BioSciences @codiakbio]

This week our CTO, Konstantin Konstantinov welcomed Professor Kenneth Witwer of Johns Hopkins University and President-elect of @IsevOrg to give a talk about EV biodistribution & immunogenicity with our team. Thanks to Professor Witwer for a compelling presentation and dialogue!

[Codiak BioSciences @codiakbio]

Our CEO Doug Williams and our CFO Linda Bain participated in a fireside chat at the 5th Annual Evercore ISI HealthCONx Conference this week. Thanks to Evercore for a great conversation about our clinical-stage programs and our platform. https://t.co/vRIegt3EXF

[Codiak BioSciences @codiakbio]

From the team at Codiak, we’d like to wish everyone and their families a very Happy Thanksgiving!

[Codiak BioSciences @codiakbio]

CEO Douglas Williams on the data we presented at SITC, and our ongoing Phase 1 clinical study of exoASO-STAT6, which is on track for data in the first half of 2023. https://t.co/ZSwtrpOx5l

[Codiak BioSciences @codiakbio]

We presented very encouraging preclinical data on two of our programs, exoASO-STAT6 and exoASO-C/EBPβ, at SITC 2022. Our CSO, Sriram Sathy provides the high-level takeaways. https://t.co/ZSwtrpOx5l

[Codiak BioSciences @codiakbio]

Recognizing Sriram Sathy for his presentation today at NIBIT on how we engineer our exosome therapeutics to reprogram tumor-associated myeloid cells.

[Codiak BioSciences @codiakbio]

Our CSO, Sriram Sathyanarayanan, on the protection offered by our pan beta-coronavirus vaccine candidate, which based on this data, may limit the virus’ ability to mutate and evade protection. https://t.co/YgWG64Nso8

[Codiak BioSciences @codiakbio]

Today we present preclinical data at the Vaccines Summit 2022 in Washington DC, showing our pan beta-coronavirus vaccine candidate protects against multiple known variants of SARS-CoV-2 and seven sarbecoviruses circulating in bats. https://t.co/YgWG64Nso8

[Codiak BioSciences @codiakbio]

Long-term stability is a critical issue when it comes to therapeutics both clinically and commercially, and Lisa Jacob, our Scientist I, will present how we’ve achieved this with our exosome constructs.

[Codiak BioSciences @codiakbio]

Konstantin Konstantinov and Aaron Noyes will both present next week at the ICB V conference in Barcelona, highlighting how exosomes are helping lead the way as one of the newest innovations in integrated continuous processing of bionanoparticles.

[Codiak BioSciences @codiakbio]

At SITC, we’ll present new preclinical data on two of our systemically administered exosome therapeutic candidates which target macrophages and have previously demonstrated potent monotherapy activity in preclinical models. We’ll see you in Boston! https://t.co/kDuCadxipi

[Codiak BioSciences @codiakbio]

Dalia Burzyn will present next week on exoASO-STAT6, a novel investigational therapeutic candidate that induces reprogramming of tumor-associated macrophages, promotes CD8 T-cell mediated adaptive immune responses & shows potent monotherapy activity in several preclinical models.

[Codiak BioSciences @codiakbio]

Yushi Feng, our Vice President of Regulatory Affairs, will present next week a regulatory perspective on how Codiak is bringing the new modality of exosome-based therapeutics to first-in-human studies.

[Codiak BioSciences @codiakbio]

Zhilin Chen will present at the 2022 #ISV Annual Congress on our beta-coronavirus vaccine candidate. We observed cross-neutralizing antibody protection​ vs SARS-CoV-2 & VOC, SARS-CoV-1, and bat coronaviruses, & saw durable IgG humoral immunity​ for over 10 months.

[Codiak BioSciences @codiakbio]

Codiak’s Konstantin Konstantinov and Scott Estes, teamed up with Jamey Young, an expert in exosomes from Vanderbilt, to write a review of exosomes as Tx. As leaders in the field, we are proud to provide this overview of the potential of exosomes. https://t.co/K5hRI1ttGZ

[Codiak BioSciences @codiakbio]

We’ll be participating in two upcoming investor conferences - including a fireside chat at the BTIG Biotech Conference and a panel entitled “For Your IOnly – Progress, Challenges in Immuno-Oncology,” at Wedbush PacGrow. We hope to see you there. https://t.co/6IXNiBrXsn